Cargando…
A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
OBJECTIVES: A global unmet medical need exists for effective treatments for persistent, recurrent, or metastatic cervical cancer, as patients have a short life expectancy. Recently, immunotherapies have shown promising survival benefits for patients with advanced forms of cancer. Axalimogene filolis...
Autores principales: | Basu, Partha, Mehta, Ajay, Jain, Minish, Gupta, Sudeep, Nagarkar, Rajnish V., John, Subhashini, Petit, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929492/ https://www.ncbi.nlm.nih.gov/pubmed/29538258 http://dx.doi.org/10.1097/IGC.0000000000001235 |
Ejemplares similares
-
ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer
por: Petit, Robert G, et al.
Publicado: (2014) -
High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer
por: Ghamande, Sharad, et al.
Publicado: (2015) -
Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
por: Rosen, Virginia M., et al.
Publicado: (2017) -
Listeriolysin O is a target of the immune response to Listeria monocytogenes
Publicado: (1992) -
Distinct Neurotoxicity Profile of Listeriolysin O from Listeria monocytogenes
por: Maurer, Jana, et al.
Publicado: (2017)